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Abstract. The objectives of this study were: 1) to evaluate the safety and efficacy of combination artesunate (AS)/
amodiaquine (AQ) therapy, and 2) to determine the difference between recrudescence and resistance. An in vivo
efficacy study was conducted in Equatorial Guinea. A total of 122 children 6–59 months of age from two regional
hospitals were randomized and subjected to a 28-day clinical and parasitological follow-up. A blood sample on Whatman
paper was taken on Days 0, 7, 14, 21, and 28 or on any day in cases of treatment failure, with the parasite DNA then being
extracted for molecular analysis purposes. A total of 4 children were excluded, and 9 cases were lost to follow-up. There
were 17 cases of late parasitological failure, 3 cases of late clinical failure, and 89 cases of adequate clinical and
parasitological response. The parasitological failure rate was 18.3% (20 of 109) and the success rate 81.70% (95%
confidence interval [72.5–87.9%]). After molecular correction, real treatment efficacy stood at 97.3%. Our study showed
the good efficacy of combination AS/AQ therapy. This finding enabled this treatment to be recommended to Equatorial
Guinea’s National Malaria Control Program to change the official treatment policy as of March 2008.
INTRODUCTION
Currently, malaria is one of themost important public health
problems in African countries, not only in terms of morbidity
and mortality, but also because of its socio-economic impact
and repercussions on human development. Overall, in sub-
Saharan countries, a family spends around 25% of its income
on the control and prevention of malaria.1
It is estimated that every yearmalaria gives rise to ~247million
clinical cases and as many as 881,000 deaths (91% of which are
in sub-Saharan Africa).2
In areas of Africa with stable malaria transmission, such as
Equatorial Guinea (EQG), the principal symptoms of malaria
are connected with anemia and the presence of parasites in
the placenta. Malaria is estimated to cause 10,000 maternal
deaths per annum and be responsible for 8–14% of all low
birth weight and 3–8% of all infant deaths.3 Indeed, it con-
tributes to the death of 75,000 to 200,000 children/year.4
The World Health Organization (WHO) estimates that the
probability of dying among children under 5 years of age in
EQG is 205 of 1,000 live births, with 24% of this total being
attributable to malaria.
The impact of malaria is the result of a variety of factors,
such as the species of parasite, the distribution and efficiency of
the vector, and human immunology. One of the most pressing
problems to be tackled in Africa is the rapid spread of anti-
malarial drug resistance. During recent decades, Plasmodium
falciparum has developed resistance to chloroquine (CQ) and
sulfadoxine-pyrimethamine (SP) in most African countries, two
drugs that were both financially affordable and easy to take.5
The above was shown graphically by different in vivo stud-
ies undertaken in EQG. From 1992 to 1999, the Carlos III
Institute of Health (Madrid, Spain), working in collaboration
with Equatorial Guinea’s Ministry of Health, conducted a
study on Bioko Island and concluded that resistance to CQ
was over 40% and resistance to SP was around 25% among
children under 5 years of age. On the mainland, studies under-
taken in 2001 yielded the same results.6 In 2005, following
the WHO recommendation to use combination therapy for
malaria treatment, a trial was performed in Equatorial
Guinea to evaluate the efficacy of two combinations, namely,
artesunate + sulfadoxine-pyrimethamine and amodiaquine +
sulfadoxine-pyrimethamine, with cure rates of 97.5% and
97.3%, respectively.7
In 2006, the country’s National Malaria Control Program
(NMCP) began the process of changing its malaria policy.
Based on the experience of other infectious diseases, the
WHO guideline states that a combination therapy should be
used in malaria-endemic countries. In this context, “combina-
tion therapy” should be construed as the simultaneous use of
two or more blood schizontocidal drugs having independent
modes of action and different biochemical targets in the para-
site.8 Accordingly, the NMCP and its partners decided to use
artesunate (AS) + amodiaquine (AQ) as a first line of treat-
ment of non-severe falciparum malaria.
When a country like EQG is situated in a high malaria-
incidence area with a high transmission rate, it is necessary
to establish a method to differentiate recrudescence from
re-infection in an in vivo study. Methods such as polymorphic
gene (msp-1 andmsp-2) analysis9 or microsatellite analysis are
useful for this purpose.10
The objectives of this study were: 1) to evaluate the efficacy
of the AS/AQ combination as a first line of treatment of
uncomplicated malaria in Equatorial Guinea, and 2) to deter-
mine the difference between recrudescence and resistance
and furnishing real data about resistance levels in the country.
MATERIALS AND METHODS
Study area and population. The EQG is situated in Central
Africa, in and on the Gulf of Guinea. It is divided into two
regions: the mainland area, called Rio Muni, lying between
Cameroon and Gabon; and the island region (Bioko,
Annobón, and Corisco Bay). Bioko, the largest island, lies
40 km from the Cameroon coast and Annobón. Something
like 75% of EQG’s total population—estimated at around
484,000—lives on the mainland.
Malabo, the country’s capital, is situated on Bioko Island,
which has a tropical climate, with a rainy season from May to
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October, and a dry season from December to March. This is a
mesoendemic area, documented as having a Plasmodium
index of 26% in 2006.11 Bata is the most important city on
the mainland. It too has a tropical climate, and is a meso-
hyperendemic area with a Plasmodium index of 41–75%
among children under 5 years of age (unpublished study
based on a 2006 National Prevalence Survey: Ministry of
Health and Carlos III Institute of Health).
Patient recruitment. The in vivo study was conducted from
June to December 2006 at the two regional hospitals of
Malabo and Bata, using the WHO methodology. All cases
included for assessment were drawn from the hospitals’
respective pediatric outpatient departments. The study com-
prised a prospective evaluation of the clinical and parasitolog-
ical response to an antimalarial AS/AQ combination therapy.
Because there was no evidence of treatment failure, the min-
imum sample size for ensuring 10% precision with a 95%
confidence level (95% CI) was 96 patients.12
All potentially eligible children were medically screened,
applying the following inclusion criteria: age 6 to 59 months;
no signs of severe malnutrition; slide-confirmed monospecific
P. falciparum infection; parasite density of 2,000 to 200,000
asexual parasites/microliter; axillary temperature > 37.5°C;
easy access to hospital; absence of history of hypersensitive
reaction to either of the drugs being evaluated; and informed
consent of parents or caregivers. Before being enrolled, each
child’s medical history was obtained and he/she had to
undergo a clinical examination by a physician. The following
exclusion criteria were applied, i.e., any danger signs of severe
malaria, such as inability to drink or breastfeed, vomiting,
recent history of convulsions, lethargy, and inability to sit
or stand up.
Treatment and follow-up. The clinical and parasitological
levels of all the children were evaluated for a period of
28 days. Treatment was administered during the first 3 days
under direct observation. Drugs were dissolved in water with
sugar and given with a spoon. Children were observed for
30 minutes after treatment to monitor for side effects. The
dosage given was as follows: artesunate 50 mg (Action
Medeor Lot 055585; expired 11/2008) as a single dose of
4 mg/kg/day for 3 days; and amodiaquine 150 mg (Holden
Medical, Cameroom; set 04L02; expired 11/2007) as a single
dose of 10 mg/kg/day for 3 days. The rescue treatment was
oral quinine 200 mg (Holden Medical; Lot MFF 371/05 A 01;
expired 12/2007), with a dosage of 10 mg of body weight every
8 hours for 7 days.
We used a record form that included patients’ age, sex, and
address, the name of the caregiver, a contact telephone num-
ber (where possible), and the following indicators: tempera-
ture over 6 days; drug dosages on Days 0, 1, and 2; parasitemia
on Days 0, 1, 2, 3, 7, 14, 21, and 28, or whichever day the child
was brought to the hospital; hematocrit on Days 0 and 28;
filter paper on Days 0, 14, 21, and 28 or any day in cases of
treatment failure. To avoid as many losses to follow-up as
possible, all the children were accompanied to their homes
on the first day to ascertain where they could be found/
collected and given the treatment if they failed to appear at
the hospital on one of the days of the protocol.
Giemsa-stained blood films were made and parasitemia was
quantified by a standard approximation method (number of
asexual parasites per 200 white blood cells per 40 on thick
film). A positive smear was defined as the presence of at least
one asexual form seen after examining 100 thick smear
fields. Slide quality control was conducted by re-reading 10%
of slides selected randomly, and discordant results were
referred to a third microscopist. Hematocrit was measured by
microhematocrit centrifugation on Days 0 and 28.
Classifications of treatment outcomes. Efficacy was mea-
sured on the basis of the parasitological cure rates on Day 28.
Criteria to determine treatment failure are described below.12
Early treatment failure (ETF) was deemed to be 1) devel-
opment of severe signs of or severe malaria on Days 1, 2, or 3
in the presence of parasitemia; 2) parasitemia on Day 2 higher
than on Day 0, regardless of temperature; 3) parasitemia on
Day 3, with axillary temperature > 37.5°C; or, 4) parasitemia
on Day 3 of over 25%.
Late clinical failure (LCF) was deemed to be 1) develop-
ment of severe malaria or danger signs after Day 3, with
parasitemia but without previous criteria of ETF; or 2)
parasitemia and temperature > 37.5°C on any day between
Days 4 and 28, without previous criteria of ETF.
Late parasitological failure (LPF) was deemed to be 1)
presence of parasitemia on any day between Days 7 and 28,
with temperature < 37.5°C, without previous criteria of ETF
or LCF.
Adequate clinical and parasitological response (ACPR)
was defined as absence of parasitemia on Day 28, regardless
of axillary temperature, without the patient meeting ETF,
LCF, or LPF criteria.
Other outcomes that were deemed not to constitute treat-
ment failure were withdrawal (e.g., children’s caregivers who
decided not to continue with the study); or cases where a child
could not be located, whether at the hospital, in the commu-
nity, or in the study area.
DNA extraction and molecular study. The DNA was
extracted from the blood sample and spotted onto Whatman
paper. A circle of paper (4 mm) with dried blood was cut out
and template DNA was then extracted using the SpeedTools
Tissue DNA kit (Biotools, B&M Laboratories, S.A., Madrid,
Spain). This DNA was used for the respective molecular
assays, namely; 1) semi-nested multiplex PCR for diagnosis
of malaria and confirmation of the Plasmodium species13; and
2) PCR analysis of P. falciparum microsatellite loci.10 To
distinguish cases of recrudescence from those of re-infection
in the in vivo study, P. falciparum microsatellite loci were
analyzed by PCR. Recrudescent infection was defined as any
case in which the same populations of parasites appeared on
Day 0 and on another Day (7, 14, 21, or 28). In such cases, the
sample was classified as treatment failure. When it had been
indicated in the field as treatment failure, re-infection was
then defined as any case in which a new population, not
detected on Day 0, appeared. After PCR, the result was visu-
alized by electrophoresis on agarose gel (3%) (Metaphore)
stained with ethidium bromide. This agarose has a high reso-
lution, which enables amplification fragments with little dif-
ference in the basepairs to be distinguished (the microsatellite
PCR protocol has been published by Mwangi and others10).
Ethical considerations. This study was reviewed and
approved by the health ethics committee of the EQG Minis-
try of Health and Social Welfare and the NMCP. Informed
verbal and written consent to participate was obtained from
the children’s mothers and caregivers.
Statistical analysis. The aim of this study was to evaluate
the efficacy of the drug combination in ensuring parasite
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clearance with no recrudescence during the 28 days of follow-
up. Data were transferred from a daily record form to the
WHO excel sheet14 and analyzed using Epi Info 3.4 (CDC,
Atlanta, GA). Therapeutic efficacy was calculated by dividing
the number of cases of ACPR by the number of patients
evaluated on Day 28; and the 95% CIs for efficacy were
likewise calculated.
RESULTS
From June to October 2006, 122 children from the out-
patient departments of two regional hospitals (45 fromMalabo
and 77 from Bata) were selected to evaluate the efficacy of
AS/AQ treatment. Demographic and laboratory details are
in Table 1.
Of the 122 children enrolled in the study, three were
excluded on Day 0: one presented with danger symptoms
9 hours after initiating treatment, and the other two had
parasitemia of over 200,000 trophozoites per microliter. The
first was hospitalized and administered quinine by perfusion,
and the other two continued with the same combination, with
good results.
There were 10 children lost to follow-up, i.e., 2 on Day 2, 1
onDay 3, 2 onDay 4, 1 onDay 8, 2 onDay 14, and 2 onDay 21.
All of these had negative parasitemia. The follow-up rate was
10.7% (13 of 122), which is below the 20%mark recommended
by theWHOin caseswhere follow-up is conductedover 28days
(Figure 1).
The rate of P. falciparum reappearance with the combina-
tion therapy was as follows: 3 of 109 cases registered as LCF,
2.8% (95% CI: [0.60–7.80%]); and 17 of 109 cases registered
as LPF, 15.6% (95% CI: [9.40–23.80%]). The ARCP rate was
81.70% (95% CI: [72.5–87.9%]). No deaths were reported.
At enrollment, 75% of the children had mild-moderate
anemia, with hematocrit counts of between 24 and 33. Chil-
dren with hematocrit counts below this level were excluded.
By Day 28, children with anemia had declined to 50% among
those who completed the follow-up.
Although no severe reactions were recorded among the
group of children as a whole, adverse effects were present in
a low percentage. A total of five children (4.5%; 5 of 109)
presented with vomiting but they were all retreated and the
follow-up did not have to be halted.
The combination showed itself to be extremely expeditious
in terms of parasite clearance: by Day 1, 45.6% (50 of 109)
were parasitemic, by Day 2, 0.8% was parasitemic (1 of 109),
and by Day 3 the result was negative. This trend can be clearly
seen in Figure 2.
Gametocyte carriage was low with this combination, prov-
ing undetectable at baseline and persisting from Day 1 (5.8%)
to Day 14 (2.5%). No gametocytes were detected on Days 21
and 28.
Molecular correction was performed to distinguish recru-
descence or re-infection from 20 cases of resistance
detected in the field. Following molecular assay by means
Table 1
Baseline characteristics at enrollment*
Artesunate plus amodiaquine
Patients 122
% male 63.4 (78)
Age (months)
Mean (SD) 29.3 [13.9]
Range 6–58
Weight (kg)
Mean (SD) 12.4 [3.09]
Range 6–21
Temperature







*Together children from Bata and Malabo Hospitals.
†IR = interquartile rank.
Figure 1. Trial profile.
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of microsatellite analysis, all resistant cases detected in
Malabo (6) were classified as cases of re-infection. In Bata,
14 cases of resistance were detected, and with the help of
molecular analysis, 11 were classified as re-infection and
3 as real cases of resistance.
DISCUSSION
The use of an efficacious treatment with artemisinin deriv-
atives is one of the WHO’s most preferable recommendations
for decreasing the impact of malaria in sub-Saharan Africa. A
number of meetings were held in EQG between the NMCP
management and its partners, namely, theWHO, the Carlos III
Institute of Health, Medical Care Development Interna-
tional (MCDI), physicians from the public and private sector,
and other actors such as pharmacists and the like. The aim
was to change the current malaria CQ treatment protocol and
decide on the most appropriate combination for treating
uncomplicated falciparum malaria in the country. The three
possible combinations to be used in Africa are artesunate +
sulfadoxine-pyrimethamine (AS/SP), AS/AQ, and artesunate +
lumefantrine (AS/LMT; Coartem). Of these three, the AS/
AQ combination was chosen, based on the following consid-
erations: 1) it goes some way to prevent development of resis-
tance to SP, since the latter is the only safe drug for use as
intermittent preventive treatment of pregnant women and
children. Furthermore, SP is best not used in combination for
treatment but rather left as a prevention strategy; 2) in the
case of AQ/AS, adherence is said to be better than in that of
other combinations with SP, because the former has already
been marketed as a fixed-dose combination in daily doses
(Coarsucam), with different dosages for children and adults.
This formula reduces the number of tablets to be taken15; 3)
the price of AS/AQ is lower than that of Coartem, the other
fixed-dose combination16 that also guarantees adherence; and
4) EQG’s neighbors have adopted this AS/AQ combination
in their malaria policies, e.g., Gabon in 2003, Cameroon in
2004, Congo Brazzaville in 2006, and Chad in 2005 (together
with Coartem).17 It is recommended that the same treatment
be adopted at a regional level, as a means of dealing with
cross-border population movement and preventing possible
development of multi-drug resistance.
The aim of this study was to provide the NMCP with
enough information to enable it to know the baseline efficacy
of the combination to be used across the country and so mon-
itor any possible development of resistance following the
introduction of the new policy. Children were selected from
both the Bata and Malabo hospitals. The number of children
from Malabo was lower compared with Bata caused by the
decrease of prevalence; the strategy of indoor residual spraying
implemented by the Ministry of Health in collaboration with
Medical Care Development International (MCDI). Malabo
also has a lower Plasmodium index, thereby making it more
difficult for children who met the inclusion criteria to be
found at this hospital. Nevertheless, no statistical differences
in resistance were detected between the two areas.
Our study showed that the AS/AQ combination is effica-
cious for use as a first-line treatment in EQG. The ACPR rate
after PCR correction was 97.3%. This result is similar to those
obtained in many African countries. A study conducted in
the Sudan, which compared the efficacy of AS/AQ to that of
AS/SP, reported an ACPR of 95.2% with AS/AQ.18 Similarly,
the PCR-corrected efficacy of AS/AQ was 100% in another
efficacy study with a 28-day follow-up, which targeted children
in Nigeria.19 Finally, a study undertaken in Tanzania to ascer-
tain the baseline resistance of two different combinations,
namely, Coartem and AS/AQ, reported the efficacy of the
latter as being 93.8%.20
The use of microsatellites helped detect the number of genu-
ine cases of resistance.Of a total of 20 cases detected in the field,
only three were classed as genuinely resistant; the remaining
17 were cases of reinfection, a very common phenomenon in a
Figure 2. Parasite clearance by day of follow-up, comparing this study with another one carried out the previous year, using the same
methodology. Clearance rates were faster in the AS/AQ group (efficacy of Artesunate + Sulfadoxine-Pyrimethamine [AS + SP] and Amodiaquine +
Sulfadoxine-Pyrimethamine [AQ + SP]) for uncomplicated falciparum malaria in Equatorial Guinea (Central Africa), Charle and others.7
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country such as EQG, with a high level of transmission. The
use of molecular analysis of, for example, msp-1 and msp-2
genes or, in this particular case, of microsatellite loci of P.
falciparum, is invaluable for the purposes of such differentia-
tion, and we highly recommend that it be used in in vivo stud-
ies conducted in countries having a high transmission rate.
Parasite clearance was extremely swift, with around 50% of
the children testing negative after receiving the first dose. By
Day 1, half the children, and by Day 2, < 1% was parasitemic.
This rapid and substantial reduction in parasite biomass is
caused by the artemisinin derivatives. Unlike other antimalar-
ial treatments, this drug kills several blood stages of the para-
site. Comparison of these results to those of the study carried
out 1 year earlier in EQG using another two combinations—
AS/SP and AQ/SP—showed that in these cases parasite clear-
ance had been slower, i.e., by Day 1, two-thirds and over 90%,
and by Day 2, 3% and half the children were positive, using
AS/SP and AQ/SP, respectively (Figure 2). Other studies
conducted in different African countries yielded results simi-
lar to ours. In a study undertaken in Uganda in 2007, the
difference in parasitemia clearance using combinations with
and without artemisinin derivatives was described: by Day 2,
just 3% in the first group as opposed to 48% in the second
group were positive.21 In that same year, another study in
Senegal, using five different combination therapies, showed a
parasitemia of 5% by Day 2 with AS/AQ. Clearance was even
faster using Coartem.22
The combination was well tolerated, no severe reactions
were recorded, and in no case did the treatment have to be
halted. The principal adverse effects were gastrointestinal dis-
orders, with 4.5% of children presenting with vomiting on
Day 1 of follow-up. These data are similar to another study
conducted in Senegal using the same combination, where
4.7% of children presented with vomiting.23 Some caregivers
reported that children also suffered from asthenia. Insofar
as this symptom is concerned, it is difficult to determine
whether it is caused by the malaria treatment or is related to
the disease itself. No severe reactions linked to amodiaquine
use as a prophylactic, such as leukopenia or agranulocytosis,
was recorded.
The results of our study have already had important impli-
cations on policies in relation to the fight against malaria:
1. A recentWHO recommendation envisages the use of com-
bination therapy for treating uncomplicated falciparum
malaria, with an efficacy of over 95%. This good result in
terms of AQ/AS efficacy and safety furnishes the NMCP
with a baseline against which tomonitor any possible devel-
opment of resistance.
2. EQG plans to start using this new combination during the
coming months, as its main method of treatment of combat-
ing malaria. Thereafter, efficacy will have to be re-evaluated
every 2 years to be able to change policy, before drug resis-
tance has a chance to rise to unacceptable levels.
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